IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...
MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...
Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...
Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) missed analyst estimates by 24%. Looking ahead, revenue ...
In a report released on November 8, Brian Abrahams from RBC Capital maintained a Buy rating on IGM Biosciences (IGMS – Research Report), ...
Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial ...
Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) dropped 7.8% on Friday .The stock traded as low as $12.82 and last traded at $13.25. Approximately 108,339 shares changed hands ...
Igm Biosciences ( (IGMS)) has released its Q3 earnings. Here is a breakdown of the information Igm Biosciences presented to its investors. IGM Biosciences, a clinical-stage biotechnology company ...
Igm Biosciences (IGMS) has disclosed a new risk, in the Share Price & Shareholder Rights category. Igm Biosciences faces significant risks that could adversely impact its business and financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback